Evidence map›Paper›PMID 28584254›Full record

ArticleLeukemia2018

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV

A Burns, R Alsolami, J Becq, B Stamatopoulos, A Timbs, D Bruce, P Robbe, D Vavoulis, R Clifford, M Cabes and 11 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Chromoanagenesis Detection in Chronic Lymphocytic Leukemia.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Towards precision medicine in lymphoid malignancies.Journal of internal medicine · 2022
    Review
  14. Cancers · 2022
    Article
  15. SAMHD1 in cancer: curse or cure?Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  16. Frontline treatment in CLL: the case for time-limited treatment.Hematology. American Society of Hematology. Education Program · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 4 countries.

A BurnsDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
R AlsolamiDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
J BecqIllumina Cambridge Ltd, Saffron Walden, UK.
B StamatopoulosDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
A TimbsDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
D BruceDepartment of Oncology, University of Oxford, Oxford, UK.
P RobbeDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
D VavoulisDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
R CliffordDepartment of Oncology, University of Oxford, Oxford, UK.
M CabesDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
H DreauDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
J TaylorWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
S J L KnightWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
R ManssonCenter for Hematology and Regenerative Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
D BentleyIllumina Cambridge Ltd, Saffron Walden, UK.
R BeekmanBiomedical Epigenomics Group, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
J I Martín-SuberoBiomedical Epigenomics Group, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
E CampoHematopathology Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
R S HoulstonDivision of Molecular Pathology, the Institute of Cancer Research, London, UK.
K E RidoutDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
A SchuhDepartment of Molecular Haematology, Oxford Molecular Diagnostics Centre, John Radcliffe Hospital, Oxford, UK.
John Radcliffe Hospital · GBUniversity of Oxford · GBConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESIllumina (United Kingdom) · GBCentre for Human Genetics · GBInstitute of Cancer Research · GBKarolinska Institutet · SE

Funding

Department of HealthWellcome TrustWellcome Trust 090532/Z/09/Z
6 · The paper itself

Abstract

Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes defined by the abundance of somatic hypermutation (SHM) affecting the Ig variable heavy-chain locus (IgHV). The molecular mechanisms underlying these subtypes are incompletely understood. Here, we present a comprehensive whole-genome sequencing analysis of somatically acquired genetic events from 46 CLL patients, including a systematic comparison of coding and non-coding single-nucleotide variants, copy number variants and structural variants, regions of kataegis and mutation signatures between IgHV

Indexed as

AgedAged, 80 and overCytidine DeaminaseEnhancer Elements, GeneticFemaleGenes, Immunoglobulin Heavy ChainHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedMutationPromoter Regions, GeneticProto-Oncogene ProteinsSAM Domain and HD Domain-Containing Protein 1Cytidine DeaminaseImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionProto-Oncogene ProteinsSAM Domain and HD Domain-Containing Protein 1

Identifiers

PMID28584254
PMCPMC5808074
OpenAlexW2621874387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.